TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

We recently published 10 Stocks Bleeding Early. TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the companies that stood stronger last week.

TG Therapeutics fell for a third day on Monday, shedding 18 percent to close at $28.72 apiece as investors soured on a lower-than-expected full-year sales guidance.

In a statement, TG Therapeutics, Inc. (NASDAQ:TGTX) raised its revenue outlook for Briumvi to a range of $570 million to $575 million from the $560 million previously, but was still lower than the $596 million as expected by analysts.

The company also upped its total global revenue target to $585 million for the full year 2025 from its previous outlook of $575 million year-on-year.

In the second quarter of the year, TG Therapeutics, Inc. (NASDAQ:TGTX) posted a net income 310-percent expansion in net income to $28.19 million from $6.88 million in the same period last year.

Total revenues were also higher by 93 percent to $141 million from $73 million in the same comparable period.

The company also swung to a net profit of $33 million from a $3.8-million net loss in the same period last year.